Takeda Pharmaceutical's Income towards Parent Company fell 957.19% to $673.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 billion, marking a year-over-year increase of 4445.12%. This contributed to the annual value of $708.5 million for FY2025, which is 2907.44% down from last year.
Latest data reveals that Takeda Pharmaceutical reported Income towards Parent Company of $673.3 million as of Q4 2025, which was down 957.19% from $4.7 billion recorded in Q3 2025.
In the past 5 years, Takeda Pharmaceutical's Income towards Parent Company ranged from a high of $4.7 billion in Q3 2025 and a low of -$97.7 million during Q1 2022
In the last 5 years, Takeda Pharmaceutical's Income towards Parent Company had a median value of $827.6 million in 2022 and averaged $1.3 billion.
Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 1166003.88% in 2021, then tumbled by 10524.86% in 2022.
Over the past 5 years, Takeda Pharmaceutical's Income towards Parent Company (Quarter) stood at $508.2 million in 2021, then skyrocketed by 65.92% to $843.2 million in 2022, then increased by 27.73% to $1.1 billion in 2023, then plummeted by 30.86% to $744.6 million in 2024, then dropped by 9.57% to $673.3 million in 2025.
Its Income towards Parent Company was $673.3 million in Q4 2025, compared to $4.7 billion in Q3 2025 and $1.5 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value